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Abstract Astrocytes are involved in many key physiolog-
ical processes in the brain, including glutamatergic trans-
mission, energy metabolism, and blood flow control. They
become reactive in response to pathological situations, a
response that involves well-described morphological alter-
ations and less characterized functional changes. The
functional consequences of astrocyte reactivity seem to
depend on the molecular pathway involved and may result
in the enhancement of several neuroprotective and neuro-
trophic functions. We propose that a selective and con-
trolled activation of astrocytes may switch these highly
pleiotropic cells into therapeutic agents to promote neuron
survival and recovery. This may represent a potent
therapeutic strategy for many brain diseases in which
neurons would benefit from an increased support from
activated astrocytes.
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Abbreviations
AD Alzheimer’s disease
ALS Amyotrophic lateral sclerosis
BrdU Bromodeoxyuridine
CNTF Ciliary neurotrophic factor
COX2 Cyclooxygenase 2
GFAP Glial fibrillary acidic protein
FGF Fibroblast growth factor
KO Knockout
HD Huntington’s disease
IGF-1 Insulin-like growth factor 1
IL Interleukin
iNOS Inducible nitric oxide synthase
LPS Lipopolysaccharide
MCAO Middle cerebral artery occlusion
MRI Magnetic resonance imaging
NGF Nerve growth factor
NFκB Nuclear factor-κ B
NMDA N-Methyl-D-aspartate
PET Positron emission tomography
STAT3 Signal transducer and activator of transcription 3
SOCS3 Suppressor of cytokine signaling 3
SOD Superoxide dismutase
SCI Spinal cord injury
TGFβ Transforming growth factor β
TNFα Tumor necrosis factor α
Astrocytes and Brain Diseases
Over the last 20 years, a new field of research has emerged
focusing on astrocytes, the most abundant glial cell type in
the brain. Extensive study has led to many surprising
discoveries regarding the role of these cells and their
importance for brain function. Some of the functions of
astrocytes were first proposed by Ramon y Cajal, more than
a century ago, when he described the unique anatomical
properties of these cells [1]. Astrocytes—with their endfeet
extending toward blood vessels on one side and enclosing
synapses on the other—are ideally situated to control
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metabolic supply, blood flow, ionic homeostasis, and
neurotransmitter levels [2]. More recently, studies have
suggested that in addition to their supportive role toward
neurons, astrocytes play an active role in neuronal
transmission and synaptic plasticity [3].
It is now thought that astrocytes are organized into
nonoverlapping spatial domains [4–6]. In the rodent brain, a
single astrocyte domain may encompass more than 100,000
synapses that may be regulated in a coordinated fashion by
gliotransmitters released from this cell [5, 6]. Another key
anatomical feature of astrocytes is their interconnection by
gap junctions (two apposed hemichannels of connexins)
that forms a syncytium facilitating transfer of information
and metabolites over distance [7]. Because of these peculiar
anatomical properties, any alteration in astrocyte function is
susceptible to have profound consequences for neuronal
activity [3].
Astrocytes have recently been shown to play a causal or
exacerbating role in several brain diseases previously thought
to be purely neuronal in origin, including status epilepticus,
schizophrenia, amyotrophic lateral sclerosis (ALS), and
Huntington’s disease (HD; for comprehensive reviews, see
[3, 8, 9]). For example, mutant huntingtin, the protein
responsible for HD, is expressed in the astrocytes of patients
and has been shown to reduce glutamate uptake by cultured
astrocytes [10]. The mutant form of superoxide dismutase 1
(SOD1) produced in the astrocytes of some familial ALS
patients is toxic to primary and embryonic stem-cell-derived
motor neurons [11]. Conversely, selective invalidation of the
gene encoding the mutant SOD1 in astrocytes slows disease
progression [12]. It has also been suggested that the amyloid
deposits observed in Alzheimer’s disease (AD) may result
from the dysfunctional degradation of amyloid fibrils by
astrocytes [13]. Therefore, astrocyte dysfunction may play an
unsuspected role in the occurrence and exacerbation of many
diseases. These cells may therefore be a promising new
therapeutic target for many of these pathological conditions,
particularly given the unique ability of astrocytes to become
reactive, which may be accompanied by marked functional
alterations of potential benefit to damaged neurons.
This review will address the following issues: What are
the main morphological and functional features of reactive
astrocytes? Are these features unique and universal or
dependent on the stimulus involved? Do reactive astrocytes
promote, exacerbate, or combat pathogenic processes?
Could novel therapeutic strategies for brain diseases be
based on a targeted activation of astrocytes?
In the following paragraphs, we will use the term
“reactive astrocytes” or “astrogliosis” as a state of astro-
cytes that is induced by any pathological situation by means
of endogenous mechanisms, while “activated astrocytes”
will refer to a state that is induced experimentally by
pharmacological or genetic manipulations.
General Features of Reactive Astrocytes
Astrocyte reactivity is a general term encompassing
changes in both the morphology and function of astrocytes
in response to any pathological condition. The pathological
stimulus may be an acute injury, such as mechanical lesions
of brain parenchyma, brain trauma, ischemia, infection, or a
chronic deleterious situation such as neurodegenerative
diseases or aging [14–16]. Astrocyte reactivity is generally
associated with microglial reactivity and, in some cases,
leukocyte recruitment. Microglia, the resident immune cells
of the brain, may in fact be responsible for the subsequent
activation of astrocytes and may coordinate complex
processes of neuroinflammation [17]. This review will
focus on astrocyte activation and will not specifically
address the potential dual effects of reactive microglia and
immune cell infiltration for neuronal survival and brain
recovery. Several comprehensive reviews have already been
published on this interesting topic [18–20].
The reactive state of astrocytes was initially defined on
the basis of morphological criteria. Reactive astrocytes have
both hypertrophic processes and soma and overexpress
intermediate filaments (glial fibrillary acidic protein
(GFAP), vimentin, and nestin [21, 22]; see Fig. 1). This
definition was recently refined by studies using dye-filling
[23] or diolistic labeling [24] of reactive astrocytes and
three-dimensional reconstruction of confocal images. Re-
active astrocytes appear to have thicker main processes than
resting astrocytes, without any significant alteration in their
overall domain volume [23]. Their processes also tend to
overlap more at the domain boundaries after epileptic
seizures, but not during chronic neurodegenerative diseases
[24].
After a local disruption of the brain parenchyma, reactive
astrocytes extend their processes in a single plane forming a
glial scar that demarcates the lesioned area from healthy
parenchyma. This type of astrocyte reactivity, called
anisomorphic gliosis, is irreversible [16]. By contrast, with
less focal injuries such as chemical lesions or during
chronic diseases, reactive astrocytes are more evenly
distributed and have randomly orientated processes, a
reversible phenomenon called isomorphic gliosis. Thus,
even if reactive astrocytes display common features
(hypertrophy and upregulation of intermediate filaments),
other characteristics may depend on the stimulus involved
(see below).
The classic definition of astrocyte reactivity involves
cellular proliferation; however, the intensity of astrocyte
proliferation appears quite variable depending on the model
studied and the techniques used. Early reports using
bromodeoxyuridine (BrdU) labeling or radioactive thymi-
dine incorporation suggested that limited astrocyte prolif-
eration occurred after brain injury (less than 5% of total
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reactive astrocytes) and that the apparent increase in the
number of astrocytes in pathological conditions might be
linked to the production of larger amounts of GFAP (see
references in [16]). However, a recent study based on
genetic mapping with inducible Cre-mediated recombina-
tion in reactive astrocytes and lentivirus-tagging suggested
that adult astrocytes are a significant source of proliferating,
reactive astrocytes in response to stab wound injury in mice
[25]. They found that up to 40% of tagged adult astrocytes
incorporated BrdU after injury. The use of this elegant
technique in other models of astrogliosis should provide a
more general assessment of the degree of proliferation.
More functional markers of astrocyte reactivity include
an increase in the levels of certain cytokines, such as
interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF),
adhesion/recognition molecules, as well as other proteins
generally associated with detrimental effects such as
calcium-binding protein S100β, inducible NO synthase
(iNOS), and cyclooxygenase 2 (COX2; reviewed in [14,
15]). Following acute injuries, astrocytes express immediate
early genes such as c-fos and heat shock protein genes [15].
They then overexpress intermediate filaments and undergo
morphological changes within a few hours [16]. In the case
of isomorphic gliosis, the overexpression of some of these
proteins is transient and disappears after several weeks (see
references in [16]). The time course of astrocyte reactivity is
quite complex and depends on the type of injury; the
sequence of events being even less clear in chronic
pathological states such as neurodegenerative diseases [26].
The reader is referred to several comprehensive reviews that
describe the molecular profile and time course of astrocyte
reactivity in different pathological conditions such as
ischemia [27, 28], traumatic brain injury [29], mechanical
lesions [30], or neurodegenerative diseases [18, 31].
In conclusion, while the morphological alterations of
reactive astrocytes are universal and quite easily detected,
functional changes appear much more subtle and depend on
the stimulus involved. This complex picture has contributed
to the difficulty in evaluating the functional role of reactive
astrocytes in pathological conditions.
Fig. 1 CNTF-activated astro-
cytes in the mouse hippocam-
pus. Mice were injected into the
hippocampus with a lentiviral
vector containing the cDNA for
the cytokine CNTF (CNTF) or
the cDNA for β-galactosidase
(Control). Two months later,
astrocytes were stained for
GFAP. Activated astrocytes dis-
play classical hypertrophied
GFAP-positive processes. Scale
bar=20 μm (a, c) and 10 μm (b,
d). Unpublished data from G.
Bonvento and C.W. Shuttle-
worth
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Reactive Astrocytes: Deleterious or Protective?
Astrocytes are involved in many important brain functions.
It is therefore of key importance to evaluate whether these
functions are enhanced, lost, or unchanged when astrocytes
are in a reactive state. This dictates whether manipulation of
astrocyte reactivity is a viable therapeutic strategy for
improving neuronal survival and restoring neuronal func-
tion. Two main approaches have been used to answer this
question: prevention of endogenous astrocyte reactivity and
activation of astrocytes by pharmacological or genetic
manipulation.
Assessing the Role of Endogenous Reactive Astrocytes
One approach to interfere with astrocyte reactivity (or at
least to disrupt the glial scar) involves the knockout (KO)
of intermediate filament genes (encoding GFAP and/or
vimentin; Table 1). Knockout mice showed no develop-
mental or breeding abnormalities (see references in [21]).
However, GFAP and vimentin double-KO mice displayed
lower levels of astroglial reactivity (as seen with S100β and
nestin immunolabeling) and greater sprouting of supra-
spinal axons compared with control mice, 3 days, 1 and
5 weeks after spinal cord hemisection. These features were
associated with locomotor functional recovery 2 to 4 weeks
following injury [32]. A similar improvement in axonal
regeneration was observed in the hippocampus of double-
KO mice 2 weeks after transection of the entorhinal cortex
axons [33]. Kinouchi et al. showed that astrocytes from
these double-KO mice were more permissive for stem
cell migration and neurite extension after retinal trans-
plantation [34]. However, at earlier time points after
entorhinal axon transection (4 days), double-KO mice
displayed a lower number of synapses [33]. Indeed, a more
recent study on these mice has demonstrated that reactive
astrocytes may rather be beneficial for neuronal survival. Li
et al. found that exposing GFAP/vimentin double-KO mice
to middle cerebral artery occlusion (MCAO) resulted in an
infarct size three times larger than in littermate controls or
single-KO mice [36]. This increase in infarct size was
accompanied by a decrease in uptake of the excitotoxic
neurotransmitter glutamate and levels of plasminogen
activator inhibitor 1, a key protective protein in ischemia
[36].
Other studies have used elaborate genetic tools to more
directly address the role of reactive astrocytes. Sofroniew et al.
developed a transgenic mouse expressing the herpes simplex
virus type 1-thymidine kinase “suicide gene” under control of
the mouse GFAP promoter (Table 1). The enzyme encoded
by this gene phosphorylates gangiclovir, preventing further
elongation of the newly synthesized DNA and triggering the
death of dividing cells. This results in the specific ablation of
reactive astrocytes that have strong GFAP promoter activity
and are undergoing proliferation. Sofroniew et al. used this
model to investigate the role of reactive, dividing astrocytes
Table 1 Main genetic approaches to investigate the role of reactive astrocytes in vivo
Genetic construct Effect Model of
astrogliosis Injury
Main outcomes Reference
GFAP-vimentin KO Disruption of cytoskeleton
in reactive astrocytes
Spinal cord
hemisection
Increased axonal sprouting functional recovery − [32]
Entorhinal cortex
axon transection
Improved axonal regeneration at 2 weeks
Decrease in synapse number at 4 days
+/− [33]
Cell transplant in
the retina
Increased stem cell migration and neurite
extension
− [34]
Retinal detachment Improved photoreceptor survival − [35]
MCAO Increase in infarct size + [36]
PromGFAP-TK
(+oral ganciclovir)
Ablation of dividing
reactive astrocytes
Forebrain stab
wound
Increase in neurite outgrowth lesion
exacerbated
+/− [37]
Spinal cord injury Lesion and motor symptoms exacerbated + [38]
Traumatic cortical
injury
Lesion exacerbated when mild injury, no effect
on severe injury
+ [39]
PromNestin-Cre X
STAT3loxP
Inhibition of astrocyte
reactivity
Spinal cord injury Lesion aggravated and more severe symptoms + [40]
PromNestin-Cre X
SOCS3loxP
Enhancement of astrocyte
reactivity
Spinal cord injury Reduced lesion and improved motor
symptoms
+ [40]
This table reports only the main studies on the functional role of reactive astrocytes in vivo that are based on genetic targeting of astrocytes
through the use of cell type-specific promoters. Many other studies with a nonselective KO or overexpression (of cytokines for example) have
been carried out but are not mentioned here. See [41] for review on the outcomes of such experiments. Signs “+”, “−”, and “+/−” refer,
respectively, to beneficial, detrimental, or mixed effects of reactive astrocytes on the injury outcome
Prom promoter
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in various acute pathological conditions, including forebrain
stab wound [37], traumatic cortical brain injury [39], and
stab or crush spinal cord injury (SCI) [38]. The absence of
dividing reactive astrocytes limited glial scar formation,
allowing greater neurite outgrowth in the forebrain stab
wound model [37]. However, the ablation of reactive
astrocytes greatly increased the severity of all these lesions:
Blood brain barrier repair was impaired, immune cell
infiltration levels were higher, and neuronal death was
significantly enhanced. In the forebrain stab wound model,
memantine (a N-methyl-D-aspartate (NMDA) glutamate
receptor antagonist) partially prevented neuronal death in
the CA1 region of the hippocampus of reactive astrocyte-
ablated mice [37], highlighting the key role of reactive
astrocytes in promoting glutamate homeostasis. In the SCI
model, significant levels of oligodendrocyte death accompa-
nied by severe demyelination were also observed in reactive
astrocyte-ablated mice, together with less favorable motor
outcomes [38]. Myer et al. used controlled cortical impacts
of different intensities to produce either moderate or severe
cortical lesions leading to 18% and 88% loss of cortical
tissue, respectively, and found that the ablation of dividing
reactive astrocytes affected only moderate injuries [39]. This
last observation suggests that the capacity of reactive
astrocytes to promote brain recovery is limited, and
therefore, stimulating this endogenous response to brain
insult may constitute an efficient therapeutic strategy.
Okada and colleagues provided more direct evidence for
beneficial roles of reactive astrocytes and for the aggravating
effects of preventing astrocyte reactivity in the SCI model
(Table 1). They used a conditional KO of signal transducer
and activator of transcription 3 (STAT3) or suppressor of
cytokine signaling 3 (SOCS3) based on the Cre-mediated
recombination of these genes in reactive astrocytes [40].
STAT3 is part of the intracellular signaling pathway of many
cytokines (see “Strategies to Promote a Neuroprotective
Phenotype in Activated Astrocytes”) and seems to be
involved in astrocyte reactivity. SOCS3 is induced by STAT3
and prevents STAT3 activation, providing a negative
feedback on this pathway [42]. Okada et al. showed that
impairing astrocyte reactivity by invalidating STAT3 reduced
the migration of reactive astrocytes toward the site of injury,
increased demyelination and neuronal disruption, and wors-
ened clinical outcomes. Invalidating SOCS3 improved all
these outcomes, providing another proof-of-principle that the
endogenous astrocyte response may be insufficient and that
its stimulation may be beneficial [40].
Characterizing the Function of Experimentally Activated
Astrocytes
The role of reactive astrocytes can also be investigated by
selectively activating astrocytes independently of any
pathological processes and assessing their functional prop-
erties. This approach is based on the overexpression of known
inducers of astrocyte reactivity (see “Strategies to Promote a
Neuroprotective Phenotype in Activated Astrocytes”), and
the goal is to specifically target astrocytes, leaving other
cell types as unaffected as possible. We found that
astrocytes could be activated selectively in vivo through
lentiviral gene transfer of the cytokine CNTF or in vitro by
exposing primary mixed cultures to recombinant CNTF
[43, 44]. CNTF synthesis and release by infected cells of
the striatum (mainly neurons) induced robust and stable
activation of astrocytes that displayed classic features of
reactive astrocytes (hypertrophy, overexpression of inter-
mediate filaments) (see Fig. 1) [43]. On the contrary, the
number of CD11b- and ED1-positive microglia/macro-
phages, the expression of several neuronal markers, and
the spontaneous glutamatergic activity of striatal neurons
remained unaffected by CNTF [43]. CNTF-activated
astrocytes displayed significant alterations in two key brain
functions: glutamate homeostasis and regulation of energy
metabolism. CNTF-activated astrocytes expressed the glu-
tamate transporters excitatory amino acid transporter 1 and
2 (EAAT1 and EAAT 2) with two previously undescribed
posttranscriptional modifications (hyperglycosylation and
recruitment to functional raft domains at the membrane),
and these features were associated with significant
improvements in glutamate handling in vivo [43]. CNTF-
activated astrocytes also expressed a new set of metabolic
enzymes and transporters involved in the ketone body
pathway and fatty acid β-oxidation and displayed a higher
rate of oxidation of these alternative energy substrates to
glucose [44]. This metabolic plasticity increased the
resistance of CNTF-activated astrocytes to metabolic
injuries (glycolysis inhibition and prolonged exposure to
palmitate) and eventually improved neuronal survival in
vitro [44]. A recent study of primary cultures of mouse
astrocytes also reported that astrocyte activation by cyto-
kines (IL-1β and/or tumor necrosis factor α (TNFα))
altered the metabolic profile of these cells (enhanced
glycolysis, pentose phosphate pathway and Krebs cycle
activities and lower intracellular glycogen levels [45]).
These cytokines induced additive metabolic changes (i.e.,
enhancement of glycolysis and decreased glycogen levels)
when used in combination [45]. However, the increase in
activity of the pentose phosphate pathway and the decreased
metabolic response to glutamate were only observed in
presence of the two cytokines. This is another demonstration
that the signaling pathways responsible for astrocyte activa-
tion determine the functional outcome.
More direct neuroprotective effects of activated astro-
cytes have also been reported. Using CNTF or IL-1β to
activate spinal cord astrocytes, Albrecht et al. showed
enhanced production of fibroblast growth factor 2 (FGF-2)
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by CNTF-activated astrocytes, which was associated with
greater survival and neurite outgrowth of cocultured motor
neurons [46]. Similarly, FGF-1-activated astrocytes over-
express antioxidant enzymes and release larger amounts of
nerve growth factor (NGF) [47]. Damaged neurons express
the proapoptotic p75 form of the NGF receptor and are
eliminated by this release of NGF, whereas “healthy”
neurons may benefit from this enhanced trophic support
[47]. Activation of astrocytes by both IL-1β and TNFα in
vitro also results in significant increases in release of
glutathione [45], which is then available to neurons for their
own antioxidant defense [48].
Thus, reactive astrocytes and experimentally activated
astrocytes display marked functional changes, which may
either induce direct neurotrophic effects (increased release
of neurotrophic factors, enhanced energetic supply, etc.) or
trigger more subtle, indirect changes leading to a general
improvement in brain cell function (enhanced glutamate
uptake, reorganization of metabolic pathways, modulation
of synaptic transmission etc., Fig. 2) [62, 63]. Even the glial
scar that hinders axonal regrowth has some beneficial
consequences for the brain, demarcating the injured area
and preventing propagation of damage. Astrocyte reactivity
appears then to be a potent endogenous defense mechanism
Fig. 2 Several beneficial functions may be enhanced in reactive or
experimentally activated astrocytes. Activation of astrocytes by
pharmacological agents or induction of astrocyte reactivity in
pathological conditions may enhance the regular functions of
astrocytes. Many of them involve subtle interactions with neurons
and control their survival and correct function. Some of these
functional changes are interrelated. For example, changes in astrocyte
connectivity may have various effects on metabolite supply, synaptic
transmission, and glutamate uptake, because metabolites such as
glucose and neurotransmitters can pass through gap junctions [49].
Similarly, changes in the three-dimensional morphology of astrocytes
may modify synapse coverage and thus, neurotransmitter removal and
synapse modulation [3], Finally, changes in blood flow directly affect
nutrient availability and metabolite supply. Numbers refer to key
reviews or articles reporting an improvement in astrocyte function (in
bold) following the experimental activation of astrocytes in vitro or in
vivo (glutamate removal [43, 50, 51]; metabolic support [44];
antioxidant defense [45, 52–54]; trophic support [46, 55, 56]; K+/
water homeostasis [57, 58]). For some more complex functions
(italics), the outcome of activation is still unclear (change in
connectivity [49, 59]; synaptic modulation [60]; blood flow regulation
[61]). The background image was supplied by Servier Medical Art
236 Mol Neurobiol (2008) 38:231–241
that could be manipulated to promote neuronal survival and
recovery [20].
Strategies to Promote a Neuroprotective Phenotype
in Activated Astrocytes
In order to be a valid therapeutic approach, the activation of
astrocytes needs to be selective and controlled. Astrocyte
activation is associated with many different functional
outcomes that may have variable degrees of effectiveness
on neuronal survival. It is thus necessary to characterize
precisely the molecular cascades resulting in these different
activation states. Cytokines are key inducers of astrogliosis
(see above) [26, 64]; they activate various intracellular
pathways, including the p38/MAPK pathway [65], the
Janus kinase/STAT pathway [40], and the nuclear factor-κ
B (NFκB) pathway [66], all of which are potential targets
for promoting tight control of activation state. Some
cytokines are typically described as detrimental, inducing
excessive inflammatory processes and cell death in the
brain, while others, used at an appropriate concentration,
may have more physiological and even neuroprotective
effects [17, 67, 68].
One way to make activated astrocytes beneficial would
be to modulate their cytokine “repertoire” by favoring the
production of beneficial cytokines.
Munoz et al. showed that a specific inhibitor of p38/
MAPK decreases the production of two proinflammatory
cytokines (IL-1β and TNFα) and improves behavioral
outcomes following amyloid β injection into the mouse
hippocampus [69]. However, the functional changes in-
duced by this treatment remain unclear. Brambrilla and
colleagues have developed a transgenic mouse overexpress-
ing a dominant form of the NFκB inhibitor IκB under the
GFAP promoter [70]. These mice showed no obvious motor
or behavioral deficits, no gross anatomical alterations, or
neuronal cell loss in the spinal cord [70]. The nearly
complete abrogation of NFkB activation in astrocytes
following contusive SCI did not prevent the appearance of
GFAP-positive astrocytes after 8 weeks nor did it change
the production of some proinflammatory cytokines (TNFα,
RANTES) after 1 day. However, it decreased the injury-
induced production of other cytokines/chemokines (trans-
forming growth factor β2 (TGFβ2), MCP-1, and CXCL10)
while increasing the release of IL-6. This change in the
pattern of cytokine production was associated with a greater
sparing of white matter tracks and better functional
recovery 8 weeks after SCI [70]. This study confirms that
the NFκB pathway is a potential target for modulating the
cytokine repertoire and astrocyte activation. However,
NFκB is a key transcription factor controlling many other
prosurvival and neurotrophic genes [66], and it may be
more efficient to regulate astrocyte activation with a more
selective target. The insulin-like growth factor (IGF-1)-
calcineurin pathway has recently been identified as a
potential pathway controlling the switch between the pro-
and antineuroprotective properties of reactive astrocytes
[71]. In situ, calcineurin is expressed by reactive astrocytes
surrounding amyloid plaques in a transgenic mouse model
of AD and in the hippocampus of aged mice [72]. The
overexpression of a constitutively active form of calci-
neurin through adenoviral gene transfer in hippocampal
neuron-astrocyte cultures activates astrocytes, which dis-
play cellular hypertrophy and express several “classic”
genes of reactive astrocytes (S100β, vimentin, antioxidant
enzymes…), as seen with microarray analysis [72]. Con-
versely, in vitro calcineurin gene knockdown decreases the
production of iNOS and COX2 by reactive astrocytes after
exposure to lipopolysaccharide (LPS) [71]. But intriguingly,
the overexpression of a constitutive form of calcineurin in
astrocytes reduces their production of deleterious molecules
such as COX2, iNOS, and proinflammatory cytokines after
exposure to TNFα or LPS in vitro and in response to
penetrating cortical injury or LPS injection in vivo [71].
This suggests that calcineurin does not simply activate
astrocytes but rather modulates their phenotype. Indeed, the
authors made the interesting observation that in rat cultured
astrocytes, a delayed activation of calcineurin by IGF-1, 3
or 16 h after treatment with TNFα or LPS respectively,
could counteract their deleterious effects on neuronal
survival and astrocyte ROS production. Therefore, the
authors propose that a primary activation of calcineurin by
proinflammatory stimuli such as TNFα or LPS triggers
deleterious proinflammatory cascades and that a secondary
or sustained activation of astrocyte (by IGF-1 or by genetic
manipulation) modulates astrocyte reactivity, shifting them
toward a more protective phenotype [71].
There are some successful reports of neuroprotection
using cytokines known to activate astrocytes in relevant in
vivo models of brain diseases. Lentiviral gene transfer of
IL-6 in the rat striatum activates astrocytes (as seen with
their increased GFAP expression after 2 weeks) and
protects neurons against excitotoxic lesions [73]. Intra-
cerebroventricular injections of recombinant IL-6 signifi-
cantly decreased infarct size when injected 30 min before
and 15 min after MCAO [74]. In mouse, 1-h pre-injection
of recombinant TGFβ1 or 1-week pre-infection with an
adenovirus encoding for the TGFβ1 gene protects CA3
mouse hippocampal neurons against kainate toxicity [75].
In several primate models of HD, CNTF treatment has been
shown to be neuroprotective [76, 77]. In particular, in the
progressive model of striatal degeneration induced by the
mitochondrial toxin 3-nitropropionic acid, implantation of
capsules of cells genetically modified to secrete CNTF at
the onset of symptoms results in a significant protection of
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striatal and cortical neurons and reversal of existing motor
and cognitive deficits [76]. Thus, even a delayed activation
of astrocytes is effective, suggesting that the targeted
activation of astrocytes may be a valid therapeutic strategy
for ongoing diseases in which astrocytes may already be
reactive.
However, these experiments only provide a necessary
proof-of-principle that activation of astrocytes can be
associated with neuroprotective effects. The demonstration
that cytokine-activated astrocytes really mediate these
protective effects is still lacking. Transgenic mice, in which
astrocyte reactivity can be prevented, such as the condi-
tional STAT3 KO mice [40], may allow to test this
hypothesis.
New Molecular Tools to Target and Monitor Activated
Astrocytes
Advances in molecular biology and gene transfer technol-
ogies have made it possible to target astrocytes more
specifically and thus both to address long-standing ques-
tions regarding the role of reactive astrocytes and to use
these cells as therapeutic agents.
Conditional KO mice that express genes selectively in
astrocytes or even in reactive astrocytes are now available.
The expression of the Cre recombinase gene is placed
under the control of an astrocyte-specific promoter (such as
the GLAST, connexin 30, aquaporin 4, or apolipoprotein E
promoters) [78] or a reactive astrocyte-specific promoter
(nestin) [40]. In addition, the activity of a modified form of
the recombinase (CreERT2) can be controlled by tamoxifen
injections [79], facilitating the temporal control of the KO
process in reactive astrocytes. These are powerful models to
investigate the involvement of specific proteins in astrocyte
reactivity.
Viral vectors are useful alternative tools, and recently,
we developed lentiviral vectors, which result in high levels
of transgene expression in astrocytes, while transgene
expression is repressed in neurons (Colin et al., submitted).
These vectors will facilitate the targeted activation of
astrocytes without interfering with other cell types. Lenti-
viral vectors are very versatile experimental tools and may
carry conditional sequences to control the pattern of
transgene expression over time. Further, they can be
injected into spatially restricted structures in adult animals
from various species [80, 81]. They also represent a unique
way of selectively delivering therapeutic molecules to brain
cells while inducing minimal peripheral side effects [80,
81].
The development of potent imaging techniques, partic-
ularly for live imaging, has also opened new opportunities
to investigate the role of reactive astrocytes [3]. Such
techniques allow to evaluate changes in activated astrocytes
at the single cell level or to quantify astrocyte activation at
the brain-structure level. Specific monitoring of activated
astrocytes is particularly important in the context of a cell-
based therapeutic approach such as the targeted activation
of astrocytes. Using two-photon imaging of astrocytes
labeled with sulforhodamine 101 in the mouse cortex
[82], Nimmerjahn et al. studied the response of astrocytes
to “micro-stroke” and showed that these cells are much less
motile than microglia [83]. Similar anatomical analyses of
astrocyte activation can be performed with fluorescent
reporter genes under the control of the GFAP promoter
(or that of another intermediate filament gene induced in
reactive astrocytes [84]). Fluorescent proteins have been
used to analyze the morphological features of normal [6,
85] or reactive astrocytes [86] in brain slices and in vivo.
To obtain more global but quantitative information on
astrocyte activation, luciferase may be used as an alterna-
tive reporter gene and can be monitored and quantified by
biophotonic/bioluminescence imaging [87].
Positron emission tomography (PET) is another nonin-
vasive and quantitative imaging system, which can be used
to study the whole brain simultaneously, as opposed to
analysis of superficial structures performed with two-
photon microscopy. PET ligands available for following
neuroinflammation bind mostly to reactive microglia, but
may also label reactive astrocytes to some extent [88]. The
development of more selective ligands for reactive astro-
cytes is required to follow astrocyte activation specifically
in rodents and primates, using PET in preclinical para-
digms. Magnetic resonance imaging (MRI) is an additional
standard brain imaging technique that can be used in
rodents, primates, and humans. This technique has been
recently used to follow astrocyte reactivity 2 h following
two types of acute brain injury in rats. These studies
demonstrated that both low-flow ischemia induced by
endothelin-1 injection and NMDA-mediated excitotoxic
injury induced a detectable MRI signal (increase in T1
relaxation) [89]. Both PET and MRI may therefore be
invaluable tools in both preclinical and clinical studies to
provide noninvasive measurements of astrocyte activation
over time throughout the brain.
Conclusions
Reactive astrocytes were once thought to be detrimental
cells responsible for neuronal demise, but recent studies
have changed this view and they are now considered as
potential endogenous repair agents [62, 63, 90, 91]. The
intrinsic capacity of astrocytes to react to any type of brain
injury and to develop a broad range of defense mechanisms
makes them a very interesting therapeutic target. This is
238 Mol Neurobiol (2008) 38:231–241
particularly true, because many neurological diseases share
common pathological mechanisms such as oxidative stress,
excitotoxicity, and metabolic impairment that are linked to
functions regulated by astrocytes. The pleiotropic nature of
astrocytes makes these cells ideally suited for combating
multifactorial brain diseases. It is now necessary to develop
better molecular tools to direct and control the status of
activated astrocytes and to switch them into supportive cells
for neurons exposed to various detrimental conditions.
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